Palvella Therapeutics, Inc. (PVLA) Stock

Palvella Therapeutics, Inc. (PVLA) is a Healthcare stock trading at $112.97 (as of 2026-06-18), with a market capitalization of $1.70B and a trailing P/E of -27.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing and commercializing therapies for serious and rare genetic skin diseases. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is in Phase 3 for microcystic lymphatic malformations and Phase 2 for cutaneous venous malformations, with additional development for other mTOR-driven skin diseases.

Valuation — source: SEC EDGAR (first-party)

Price	$112.97
Market Cap	$1.70B
P/E Ratio	-27.0
Price / Book	6.95
DCF Value (model)	$-25.69
DCF Upside vs Price	-122.7%

Profitability & Growth — source: SEC EDGAR

Revenue (TTM)	$42.81M
Net Margin	-57.3%
Return on Equity	-21.2%
Current Ratio	28.88
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	-76.3%
FCF Growth (YoY)	-72.6%

Valuation vs Sector & Industry

Stock P/E	-27.0
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-228.9%
vs Industry	-256.5%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures

Top Institutional Holder	SUVRETTA CAPITAL MANAGEMENT, LLC ($143.78M)
Institutional Holders Tracked	10

Company

Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Wesley H. Kaupinen
Employees	14
Country	US
IPO Date	2015-01-02

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Immatics N.V. (IMTX)
• AnaptysBio, Inc. (ANAB)
• Amylyx Pharmaceuticals, Inc. (AMLX)
• Schrödinger, Inc. (SDGR)
• Septerna, Inc. (SEPN)
• Savara Inc. (SVRA)
• Omeros Corporation (OMER)
• Amphastar Pharmaceuticals, Inc. (AMPH)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.